Mergers and Acquisitions

Synthetic DNA business unit sold to Operon Biotechnologies

Published in Gene Therapy Weekly, July 29th, 2004

QIAGEN N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA) announced that it has sold its synthetic DNA business to a management team previously employed at QIAGEN who operated parts of this business.

The new company is backed by private investors and QIAGEN will retain a minority stake of 16%. The new company, to be named Operon Biotechnologies Inc., expects to continue to expand the leadership position QIAGEN has built in this market. QIAGEN will retain all rights and activities in its leading siRNA business including ownership of QIAGEN's proprietary TOM-amidite chemistry.

Pursuant to the terms of the agreements, QIAGEN will retain a minority...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-07-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry